Leukemia Research
Volume 26, Issue 3 , Pages 289-295 , March 2002

CD56+, NKp46+ cell line (MZ93) expressing T-cell and myeloid antigens

  • Shigeo Hashimoto

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Niigata University, Asahimachi-dori 1, Niigata City 951-8520, Japan
    • ,
  • Ken Toba

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Niigata University, Asahimachi-dori 1, Niigata City 951-8520, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-25-227-2185; fax: +81-25-227-0774
    • ,
  • Junjiro Tsuchiyama

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Niigata University, Asahimachi-dori 1, Niigata City 951-8520, Japan
    • ,
  • Takashi Abe

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Niigata University, Asahimachi-dori 1, Niigata City 951-8520, Japan
    • ,
  • Toshio Yano

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Niigata University, Asahimachi-dori 1, Niigata City 951-8520, Japan
    • ,
  • Akihito Momoi

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Niigata University, Asahimachi-dori 1, Niigata City 951-8520, Japan
    • ,
  • Kiyoshi Okazuka

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Niigata University, Asahimachi-dori 1, Niigata City 951-8520, Japan
    • ,
  • Naoko Kanazawa

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Niigata University, Asahimachi-dori 1, Niigata City 951-8520, Japan
    • ,
  • Masuhiro Takahashi

      Affiliations

    • School of Health Sciences, Faculty of Medicine, Niigata University, Niigata City 951-8510, Japan
    • ,
  • Yoshifusa Aizawa

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Niigata University, Asahimachi-dori 1, Niigata City 951-8520, Japan

Received 12 February 2001 ,Accepted 17 May 2001.

References 

  1. Kagami Y, Nakamura S, Suzuki R, Iida S, Yatabe Y, Okada Y, et al. Establishment of an IL-2-dependent cell line derived from ‘nasal type’ NK/T-cell lymphoma of CD2+, sCD3−, CD3ε+, CD56+ phenotype and associated with the Epstein–Barr virus. Br. J. Haematol. 1998;103:669–677
  2. Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, et al. A novel natural killer cell line from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14:922–930
  3. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652–658
  4. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer leukemia. Exp. Hematol. 1996;24:406–415
  5. Tsuchiyama J, Yoshino T, Mori M, Kondoh E, Oka T, Akagi T, et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein–Barr virus infection. Blood. 1998;92:1374–1383
  6. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, et al. TCGF (IL-2)-receptor inducing factor(s). I. Regulation of IL-2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 1985;134:1623–1630
  7. Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia–lymphoma. Leukemia. 2000;14:777–782
  8. Hercend T, Griffin JD, Bensussan A, Schmidt RE, Edson MA, Brennan A, et al. Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J. Clin. Invest. 1985;75:932–943
  9. Ortaldo JR, Winker-Pickett RT, Yagita H, Young HA. Comparative studies of CD3− and CD3+CD56+ cells: examination of morphology, function, T cell receptor rearrangement, and pore-forming protein expression. Cell. Immunol. 1991;136:486–495
  10. Takii Y, Hashimoto S, Iiai T, Watanabe H, Hatakeyama K, Abo T. Increase in proportion of granulated CD56+ T cells in patients with malignancy. Clin. Exp. Immunol. 1994;97:522–527
  11. Grzeschik KH, Kazazian HH. Report of the Committee on the Genetic Constitution of Chromosomes 10, 11, and 12. Cytogenet. Cell Genet. 1985;40:179–205
  12. Pedersen-Bjergaard J, Pederson M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related acute myeloid leukemia. Blood. 1995;86:3542–3552
  13. Oshimi K, Yamada O, Kaneko T, Nishinarita S, Iizuka Y, Urabe A, et al. Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia. 1993;7:782–788
  14. Chan JKC, Sin VC, Wong KF, Ng CS, Tsang WYW, Chan CH, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501–4513
  15. Toba K, Koike T, Takahashi M, Kishi K, Hashimoto S, Takahashi H, et al. Characterization and sensitivity to interleukin 2 and interferon alpha of leukemic cells from a patient with large granular lymphocytic leukemia associated with chronic active Epstein–Barr virus infection. Leuk. Res. 1997;21:941–950
  16. Suzuki R, Nakamura S. Malignancies of natural killer (NK) precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk. Res. 1999;23:615–624
  17. Vidriales MB, Orfao A, Hernandez JM, Lopez-Berges MC, Garcia MA, Canizo MC, et al. Expression of NK and lymphoid-associated antigens in blast cells of acute myeloblastic leukemia. Leukemia. 1993;7:2026–2029
  18. Thomas X, Vila L, Campos L, Sabido O, Archimbaud E. Expression of N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome. Leuk. Lymphoma. 1995;19:295–300
  19. Mann KP, DeCastro CM, Liu J, Moore JO, Bigner SH, Traweek ST. Neural cell adhesion molecule (CD56)-positive acute melogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am. J. Clin. Pathol. 1997;107:653–660
  20. Van Camp B, Durie BG, Spier C, De Waele M, Van Riet I, Vela E, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood. 1990;76:377–382
  21. Khalidi HS, Medeiros J, Chang KL, Brynes RK, Slovak ML, Arber DA. The immunophenotype of adult acute myeloid leukemia. High frequency of lymphoid antigen expression and comparison of immunophentype, French–American–British classification, and karyotypic abnormalities. Am. J. Clin. Pathol. 1998;109:211–220
  22. Suzuki R, Yamamoto K, Seto M, Kagami Y, Ogura M, Yatabe Y, et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood. 1997;90:2417–2428
  23. Murase T, Suzuki R, Tashiro K, Morishima Y, Nakamura S. Blast crisis of chronic myelogenous leukemia exhibiting immunophenotypic features of a myeloid/natural killer cell precursor. Int. J. Hematol. 1999;69:89–91
  24. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl. Cancer Inst. 1972;49:891–895
  25. Kishi K, Toba K, Azegami T, Tsukada N, Uesugi Y, Masuko M, et al. Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17). Exp. Hematol. 1998;26:135–142
  26. Toba K, Koike T, Shibata A, Hashimoto S, Takahashi M, Masuko M, et al. Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils. Cytometry. 1999;35:249–259
  27. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, et al. p46, a novel natural killer cell-specific surface molecule that mediated cell activation. J. Exp. Med. 1997;186:1129–1136
  28. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 1998;188:953–960
  29. Gaffney PM, Lund J, Miller JS. FLT-3 ligand and marrow stroma-derived factors promote CD3γ, CD3δ, CD3ζ, and RAG-2 gene expression in primary human CD34+LIN-DR− marrow progenitors. Blood. 1998;91:1662–1670
  30. King A, Gardner L, Sharkey A, Loke YW. Expression of CD3ε, CD3ζ, and RAG-1/RAG-2 in decidual CD56+NK cells. Cell. Immunol. 1998;183:99–105
  31. Koike T. Megakaryoblastic leukemia: the characterization and identification of megakaryoblasts. Blood. 1984;64:683–692
  32. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421–2438
  33. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1996;87:2632–2640
  34. Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H. Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1995;85:3538–3546
  35. Reuss-Borst MA, Jasconek K, Muller CA. Acute undifferentiated leukemia with an unusual CD7+CD56+CD33+ immunophenotype of NK progenitors [letter]. Leukemia. 1996;10:923–924
  36. Scott AA, Head DR, Kopecky KJ, Appelbaum FR, Theil KS, Grever MR, et al. HLA-DR−, CD33+, CD56+, CD16−, myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French–American–British acute myeloid leukemia-M3. Blood. 1994;84:244–255
  37. Phillips JH, Hori T, Nagler A, Bhat N, Spitz H, Lanier LL. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3ε,δ proteins. J. Exp. Med. 1992;175:1055–1066
  38. Long H, Gaffney P, Mortari F, Miller JS. CD3γ, CD3δ, CD3ζ mRNA in adult human marrow hematopoietic progenitors correlates with surface CD2 and CD7 expression. Exp. Hematol. 1996;24:1402–1408
  39. Drexler HG, Matsuo Y. Guidelines for the characterization and publication of human malignant hematopoietic cell lines. Leukemia. 1999;13:835–842
  40. Drexler HG, Dirks WG, MacLeod RAF. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia. 1999;13:1601–1607

PII: S0145-2126(01)00115-1

Leukemia Research
Volume 26, Issue 3 , Pages 289-295 , March 2002

Article Tools

* Image Usage & Resolution